Observational Study
Copyright ©The Author(s) 2017.
World J Gastrointest Oncol. Aug 15, 2017; 9(8): 327-332
Published online Aug 15, 2017. doi: 10.4251/wjgo.v9.i8.327
Table 1 Clinicopathological characteristics of the two groups n (%)
Group A (n = 109)Group B (n = 83)P value
Age, median [IQR], yr66 [61-74]72 [63-78]0.0009
Male92 (84.4)72 (86.7)0.7
Diabetes mellitus24 (22.0)12 (14.5)0.2
Complicated other malignant disease27 (24.8)22 (26.5)0.9
Helicobacter pylori status0.4
Positive8257
Post eradicated2326
Negative40
Tumor location0.9
Upper1011
Middle5739
Lower4233
Tumor size, median [IQR], mm15 [10-20]15 [12-22]0.3
Macroscopic type0.5
0-I93
0-IIa6752
0-IIb2625
0-IIc73
Differentiated type109 (100)81 (97.6)0.2
Tumor depth0.1
M9780
SM123
Table 2 Endoscopic characteristics of the two groups n (%)
Group A (n = 109)Group B (n = 83)P value
Severe atrophy87 (79.8)74 (89.2)0.1
Intestinal metaplasia49 (45.0)48 (57.8)0.08
Gastric xanthoma35 (32.1)45 (54.2)0.003
Table 3 Endoscopic score of risk for gastric cancer of the two groups
Group A (n = 109)Group B (n = 83)P value
Atrophy0.005
040
160
29983
Intestinal metaplasia0.1
06035
13334
21614
Fold swelling0.6
09973
11010
Nodular gastritis1.0
010983
100
Diffuse redness0.5
040
12325
28258
Total score, median [IQR]4 [4-5]4 [4-5]0.1
Table 4 Multivariate analysis of predictive marker of metachronous and synchronous gastric cancer
Odds ratioP value
Age1.04 (1.01-1.08)0.02
Male1.38 (0.57-3.34)0.47
Severe atrophy1.68 (0.70-4.05)0.25
Intestinal metaplasia1.35 (0.71-2.54)0.36
Gastric xanthoma2.11 (1.14-3.99)0.02